Search Immortality Topics:

Page 10«..9101112..2030..»


Category Archives: Nano Medicine

Growth Opportunities in mRNA Therapeutics, Genomics Platforms, Microbiome Testing, Would Healing Solutions, and AI-Based Diagnostics -…

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in mRNA Therapeutics, Genomics Platforms, Microbiome Testing, Would Healing Solutions, and AI-Based Diagnostics" report has been added to ResearchAndMarkets.com's offering.

The increase in clinical utility of liquid biopsies and other diagnostic assays, which is driven by AI has been discussed. The TOE issue also highlights developments in enabling technologies for microbiome analysis, and personalized health solutions based on microbiome testing. A few emerging technologies around DNA synthesis, next generation mRNA therapeutics and diagnostics have been highlighted. Few innovations highlight developments in wound healing solutions, which include smart dressings and plant-based solutions.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/hzvh03

Excerpt from:
Growth Opportunities in mRNA Therapeutics, Genomics Platforms, Microbiome Testing, Would Healing Solutions, and AI-Based Diagnostics -...

Posted in Nano Medicine | Comments Off on Growth Opportunities in mRNA Therapeutics, Genomics Platforms, Microbiome Testing, Would Healing Solutions, and AI-Based Diagnostics -…

Anti-viral Drugs Can Be Final Solution As WHO Warns Against Lowering Our Guard To COVID-19 – Scoop.co.nz

Wednesday, 26 January 2022, 7:07 amPress Release: World Nano Foundation

Suggestions that COVID-19 is on the wane have beenstrongly contradicted by the World Health Organizationssenior pandemics scientist, Dr Maria Van Kerkhove.

Andher criticism of virus complacency has fuelled calls forresearch and development of anti-viral drugs to stop allcoronaviruses at source, in addition to ongoing vaccines andtesting for COVID-19 variants.

DrVan Kerkhove, a highly regarded infectious diseaseepidemiologist and World Health Organization (WHO) Head ofthe Emerging Diseases and Zoonoses Unit, delivered herwake-up call in a BBC TV interview where she insisted thatCOVID-19 was still evolving and the world must evolve withit:

It will not end with this latest wave (Omicron)and it will not be the last variant you will hear us (WHO)speaking about unfortunately, she told BBCinterviewer Sophie Raworth.

Countries with highimmunity and vaccination levels were starting to think thepandemic is over, she added, but despite 10 billion vaccinedoses delivered globally, more than three billion peoplewere yet to receive one dose, leaving the world highlysusceptible to further COVID mutations - a global problemfor which a global solution was needed.

She alsochallenged assumptions that the COVID Omicron variant wasmild: It is still putting people in hospitaland itwill not be the last (variant). There is no guarantee thatthe next one will be less severe. We must keep the pressureup we cannot give it a free ride.

This drew aresponse from the World Nano Foundation (WNF), anot-for-profit organization that promotes many of theinnovations including nanomedicines, AI andcomputational drug development platforms, testing andvaccine development that have played vital roles infighting the COVID pandemic.

WNF Chairman PaulStannard said: We welcome Dr Van Kerkhoves timelyintervention. Too many people think we can sit back withCOVID now, forgetting lessons learned the hardway.

Such as theres always another variant justaround the corner, and testing and vaccines are not thecomplete answer.

Even if Omicron seems milder thanits predecessors though this may be due to vaccinationsand growing herd immunity who can say that a more fatalCOVID mutation will not follow, or an all-new virus iswaiting to strike.

Many other pathogens haveentered humans in last 15 years including SARs Ebola, Zikavirus and Indian Flu variants, so permanent pandemicprotection investment is vital to restoring confidence inour way of life and the global markets.

An evenolder lesson is Spanish Flu (1918-20): the death toll wasrelatively contained initially, lulling people alreadyfatigued by WW1 devastation into thinking the worst wasover.

But that virus then mutated into its mostdeadly strain, killing 50 million people when Earthspopulation numbered less than two billion. All of whichsuggests we must maintain or redouble our efforts againstCOVID-19 and other potential threats.

We havealready benefitted from greater healthcare investment andresearch due to the pandemic: experts say the first sixmonths of the emergency delivered sector progress equivalentto the previous 10 years.

This helped unusuallyrapid deployment of new and better testing and vaccines thathave driven down infection, hospitalization and deaths, butwe hope that the WHO view will now foster a new andpotentially more effective development against COVID andother threats anti-viral drugs.

Instead ofattacking the virus like a vaccine, anti-viral drugs aim tostop it functioning in the human body. Merck and Pfizer saythey have re-purposed existing drugs to do justthat.

But a better option is gathering momentumusing nanomedicine, AI and advanced computational technologyto develop all-new drugs more quickly and effectively,potentially delivering breakthroughs against many seriouskillers, including viruses, cancers and heartdisease.

WNF believes these can disrupt thetraditional pharmaceutical industry as Tesla has done in theauto industry, or SpaceX and Blue Origin have done inspace.

California-based Verseonhas developed an AI and computational drug developmentplatform and has six drug candidates, including ananti-viral drug to potentially block all coronaviruses andsome flu variants, potentially transforming pandemicprotection.

This could be on the market within 18months after securing a final $60 million investment, asmall amount compared to the $1 billion pharma industry normfor a single new drug (source: Biospace),and weighed against 5.6 million COVID deaths globally and anestimated $3 trillion in economic output (source: Statista)lost since the start of the pandemic.

Verseon Head ofDiscovery Biology Anirban Datta said: Vaccines and thecurrent anti-viral drugs are retrospective solutions thatdont treat newly emergent strains. We need a differentstrategy to avoid always being one step behind viralmutations.

So, we switched target from the virus tothe human host. If we stop SARS-CoV-2 (COVID-19) enteringour cells which, unlike viruses, dont mutate then we havea long-term solution.

Even better, the strategyshould work against other coronaviruses and influenzastrains that use the same mechanism as SARS-CoV-2 to infectcells a key point, since it surely wont be the lastpandemic to affecthumanity.

Scoop Media

Become a member Get our free pnui

Excerpt from:
Anti-viral Drugs Can Be Final Solution As WHO Warns Against Lowering Our Guard To COVID-19 - Scoop.co.nz

Posted in Nano Medicine | Comments Off on Anti-viral Drugs Can Be Final Solution As WHO Warns Against Lowering Our Guard To COVID-19 – Scoop.co.nz

Predictions 2022: Year of personalisation of healthcare and therapies – Fortune India

What could change in the next 5 years? 2022 is the foundation year for an unprecedented amount of collaborative research and innovation. As we move ahead, an integrated healthcare industry will create new ways to diagnose patients; prevention will actually become the cure; and technology will provide unprecedented levels of patient information, making it easier than ever before to find therapies to treat individual-specific conditions, or even specific individuals.

In the next decade, global healthcare will blur the lines between different segments, and even sectors. The traditional distinction between different parts of the healthcare industry clinical practice, diagnostics, devices and pharmaceuticals has already begun to disappear. So will the barriers between innovators, service providers and technologists.

Digital health is already changing the face of diagnosis and drug discovery. In the future, new healthcare platforms will provide remote care to patients, smart sensors will monitor body chemistry and vital signs, and identify potential disease risk. Manufacturing technology will be increasingly refined and complex but not complicated.

That artificial intelligence (AI) and machine learning (ML) will accelerate along the spectrum of healthcare is a given. Robotics and virtual reality have already begun and will continue to aid doctors in the operation theatre to conduct surgery with much higher precision. Sensors monitoring vital signs, triggering alerts and even treatment are already making their mark.

Go here to see the original:
Predictions 2022: Year of personalisation of healthcare and therapies - Fortune India

Posted in Nano Medicine | Comments Off on Predictions 2022: Year of personalisation of healthcare and therapies – Fortune India

Global Healthcare Nanotechnology (Nanomedicine) Market Scope 2021-2027 Industry Growth, Business Opportunity, and Leading Players Industrial IT -…

Research Report on Healthcare Nanotechnology (Nanomedicine) Market added by In4Research consist of Growth Opportunities, Development Trends, and Forecast 2026. The Global Healthcare Nanotechnology (Nanomedicine) Market report covers a brief overview of the segments and sub-segmentations including the product types, applications, companies & regions. This report describes the overall Healthcare Nanotechnology (Nanomedicine) Market size by analyzing historical data and future forecast.

The Healthcare Nanotechnology (Nanomedicine) Market Report includes:

To Get Sample Copy of Healthcare Nanotechnology (Nanomedicine) Market Report with Complete TOC, Figures & Graphs Connect with us at https://www.in4research.com/sample-request/23369

Major Key Players Covered in The Healthcare Nanotechnology (Nanomedicine) Market Report include

Healthcare Nanotechnology (Nanomedicine) Market Segments and Sub-segments Covered in the Report are as per below:

By Type:

By Application:

For more Customization, Connect with us at https://www.in4research.com/customization/23369

Geographically, this report is segmented into several key Regions along with their respective countries, with production, consumption, revenue (million USD), and market share and growth rate of Healthcare Nanotechnology (Nanomedicine) in the following regions:

The Covid19 pandemic has transformed the market landscape. The market ecosystem has taken a directional shift in the way supply-side of the market is accessed. The report covers the aftermath of the Covid19 catastrophe.

Get the PDF to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies: https://www.in4research.com/impactC19-request/23369

Important Features that are under offering & key highlights of the Healthcare Nanotechnology (Nanomedicine) Market report:

Any Questions/Queries or need help? Speak with our analyst https://www.in4research.com/speak-to-analyst/23369

Major Points in Table of Content of Healthcare Nanotechnology (Nanomedicine) Market

Chapter 1. Research Objective

1.1 Objective, Definition & Scope

1.2 Methodology

1.3 Insights and Growth Relevancy Mapping

1.4 Data mining & efficiency

Chapter 2. Executive Summary

Chapter 3. Strategic Analysis

3.1 Healthcare Nanotechnology (Nanomedicine) Market Revenue Opportunities

3.2 Cost Optimization

3.3 Covid19 aftermath Analyst view

3.4 Healthcare Nanotechnology (Nanomedicine) Market Digital Transformation

Chapter 4. Market Dynamics

4.1 DROC

Chapter 5. Segmentation & Statistics

5.1 Segmentation Overview

5.2 Demand Forecast & Market Sizing

Chapter 6. Market Use case studies

Chapter 7. KOL Recommendations

Chapter 8. Investment Landscape

8.1 Healthcare Nanotechnology (Nanomedicine) Market Investment Analysis

8.2 Market M&A

8.3 Market Fund Raise & Other activity

Chapter 9. Healthcare Nanotechnology (Nanomedicine) Market Competitive Intelligence

9.1 Company Positioning Analysis

9.2 Competitive Strategy Analysis

Chapter 10. Company Profiles

Chapter 11. Appendix

Buy Full Report at: https://www.in4research.com/buy-now/23369

Key Benefits of the Report:

For More Details Contact Us:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

Go here to read the rest:
Global Healthcare Nanotechnology (Nanomedicine) Market Scope 2021-2027 Industry Growth, Business Opportunity, and Leading Players Industrial IT -...

Posted in Nano Medicine | Comments Off on Global Healthcare Nanotechnology (Nanomedicine) Market Scope 2021-2027 Industry Growth, Business Opportunity, and Leading Players Industrial IT -…

The Value of Plain Language Summaries to Patients and Caregivers – The Voice Online

AS HEALTH professionals make diagnoses every day, patients around the world take to their keyboards to research their newfound conditions. But how often is the information that these patients need accessible to them? Most journals only publish articles written for specialist readers. However, with publications now becoming increasingly accessible, patients are reading medical publications in the hope that they can better understand how to manage their conditions and/or the treatments that could be available to them.

This is where the scientific and medical publisher Future Science Group has stepped in. The progressive publisher has recognised the unmet need for patient-oriented resources and, over the past couple of years, has started publishing plain language summaries (PLS) of technical publications in its peer-reviewed journals.

What Are Plain Language Summaries?

PLS are concise recaps of technical publications. Written for lay audiences, they unpack the complex data, jargon, and concepts covered in these publications, breaking these down into their simplest terms. The summaries blend plain language with a range of media inclusions, like infographics, videos, and audio so that non-specialist readers can understand the latest developments in specific conditions, treatments, and therapies.

Here, Future Science Group reflects on two recent studies that assess a) to what extent patients read medical publications and b) how patients use the information in these publications to manage their conditions.

Do Patients Read and Use Peer-Reviewed Medical Publications?

One example of a study into how patients research their conditions is a study conducted by the healthcare marketing research company Adelphi Research. During this study, the research team asked 100 patients who have atopic dermatitis (eczema) and 50 patient caregivers to complete a survey on the information sources they use to research the condition.

Patient Survey Responses

The study, which took place in the U.S., noted that 35% of its respondents had a college education and 33% had a graduate school education. 81% of these respondents had carried out online research to investigate their condition, 77% had accessed information from healthcare providers, and 67% had sourced medical research articles themselves. Of those familiar with medical publications, 37% actively searched for these publications, while 90% accessed freely available articles.

62% of the respondents accessed medical publications via a general internet search.

49% accessed scientific journals.

19% sourced information from a library.

13% found information on patient organisation websites.

12% found information using the free search engine PubMed.

However, only 53% of respondents felt at least relatively confident in their understanding of the medical publications. Approximately half of the respondents didnt feel the publications empowered them to get involved in decision-making processes related to their eczema or stay up to date with the latest developments surrounding their condition.

Fewer than half of the respondents felt the publications empowered them to:

Optimise their disease management.

Discuss alternative treatments with healthcare professionals.

Control their condition.

Adhere to their treatment plans.

The results of this study emphasise the clear need for peer-reviewed medical content written for patient audiences. Most scientific journals lack clarity for lay audiences, and theyre often difficult to understand. However, Plain language summaries offer a valuable solution through simple language, clear structure, and media inclusions that make difficult concepts easier to grasp for patients who want to learn more about their conditions.

What Is the Value and Feasibility of Developing Plain Language Summaries of Peer-Reviewed Articles for Patients?

Another study, this one published in Therapeutic Innovation & Regulatory Science, also involved a survey that investigated whether and how patients research their conditions. Like the Adelphi Research study, this research involved a survey that confirmed patients regularly research health-related information online: 61% of the study respondents performed general internet searches on their conditions, 57% accessed patient-specific websites, and 47% searched for articles from scientific journals.

Patient Survey Responses

55 patients provided complete responses to the survey, reporting on a variety of diseases. While 23% reported on diseases concerning the central nervous system and neurology, 22% reported on pain and inflammation, 17.5% reported on autoimmune diseases, and 17.5% reported on cancers. Most of these patients consulted physicians for information about their conditions: 62% consulted specialists, 30% consulted general practitioners, and 5% consulted nurses. That said, only 17.5% of patients relied solely on a healthcare professional for information. Most also performed general internet searches, visited patient organisation websites, and accessed print and electronic scientific journals.

Almost all patients who took part in the study agreed that they wanted their physicians to discuss new information about their conditions and possible treatments with them. While 69% reported that they wanted their doctor to share all information with them, 29% reported that they only wanted their doctor to share information that was specifically relevant to them. The remaining 2% felt that information share would be of interest but that they would find it acceptable for their doctor not to share information.

Furthermore, while 96% of the patients concluded that they would be interested in sharing health information that they had found with their doctor, 45% noted that they would only feel comfortable discussing such information if they had a solid enough understanding of the material to have a conversation about it.

To conclude, 98% of patients either agreed or strongly agreed that health-related information should be easily understandable and more accessible to patients.

Patient and Caregiver Interviews

The study also involved interviews with patients and caregivers, during which patients explained that the main reasons they were researching their conditions were to improve their knowledge of their conditions and empower themselves. All interviewees noted that they would like doctors to provide more information, especially as information from the internet isnt always reliable.

Some of the information that patients hoped to gain from their doctors included information on how their disease and its management can affect daily living, epidemiologic data that offers long-term prognostic information about their disease, and information on the relevance of data from clinical studies. The respondents also agreed that handing out PLS could help doctors build good relationships with their patients while offering reliable and trustworthy resources.

Physician Insights

Meanwhile, the physicians who took part in the study concluded that PLS play an important role in improving patient communication, especially given the limited time available during many consultations. As a result, 60% of physician respondents confirmed that they would use PLS in their patient communications.

Open-access publishing and the expansion of online platforms should make communication through PLS even easier over upcoming years. This is essential given new patient engagement concepts (like shared decision making (SDM), self-management, patient empowerment, and patient-centred care), which have been widely adopted in clinical practice over the past few years. These concepts are key to helping patients become more involved in their healthcare management.

How Plain Language Summaries Fill the Demand for Patient-Centred Resources

The advent of PLS and other patient-centred resources has fuelled the evolution of the historically paternalistic relationship between patients and healthcare professionals into a collaborative partnership. The studies discussed here reinforce the evidence that patients actively seek information about their conditions to complement the information they receive from healthcare professionals, and that there is demand for plain language content written for patient audiences.

Future Science Groups publication of PLS in its open-access journals works towards filling this demand, which is only growing. These summaries prove invaluable to both patients and healthcare professionals, playing an essential role in patient dialogue, education, and accessibility.

About Future Science Group

Future Science Groups highly regarded journals publish the latest information in a wealth of scientific and medical disciplines, spanning from oncology to regenerative medicine to nanomedicine. Aside from publishing its portfolio of 34 journals, the Group also hosts a variety of events and digital hubs, where scientific communities come together to partake in essential discussions that support developments in science and medicine.

Future Science Group has been praised for its PLS initiative, which makes clinical study results and other essential information accessible to lay audiences, ensuring that all readers can access resources that help them understand diseases, treatments, and therapies.

Read more from the original source:
The Value of Plain Language Summaries to Patients and Caregivers - The Voice Online

Posted in Nano Medicine | Comments Off on The Value of Plain Language Summaries to Patients and Caregivers – The Voice Online

The Role of Nanomedicine in Transdermal Vaccine Alterantives – AZoNano

The World Health Organization has estimated the SARS-CoV-2 (COVID-19) pandemic to have caused more than 5.3 million deaths worldwide to date, and with the emergence of new variants, the urgency of effective immunization has never been more critical.

Study:The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination. Image Credit:BaLL LunLa/Shutterstock.com

Alternative means of effective delivery have been explored in a recently published article from the journal vaccines, highlighting how nanomedicine can aid the effectiveness oftransdermal antigen delivery.

The COVID-19 infection caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) has been catastrophic for the global population, with high rates of morbidity and mortality.

Schematic representation of the routes of skin penetration of active compounds. On the left, a transpedicular route consists of a. entry through hair follicle, b. entry through sweat glands, c. entry through sebaceous glands. On the right, transepidermal route. d. Transcellular pathway, e. Intercellular pathway.Image Credit:Valdivia-Olivares, R.,et al

The World Health Organization has estimated approximately 19.4 million infants globally have not been provided with vaccines. As the severity of the pandemic continues, the health of these children is at increased risk for deterioration.

This has led to the need to find alternative routes for immunization, which are effective and safe.

Transdermal routes of antigen delivery consist of a topical application to the skin where the active ingredients are absorbed systemically.

This type of method can be beneficial as it reduces first-pass metabolism and reduces the level of adverse effects. Transdermal administration provides an easy, simple, non-traumatic alternative that allows for self-administration, making this delivery route more attractive than the traditional injection method that involves needles.

However, a challenge for this delivery route for vaccine development consists of the protective barrier of the skin and the associated difficulties with overcoming the stratum corneum to enable antigen absorption.

Schematic representation of the mechanisms involved in immunization based on nanoparticles, either using combined techniques or design of nanoparticles by passive diffusion. Once the stratum corneum has been crossed, the antigens can interact with cells of the immune system already described. Image Credit:Valdivia-Olivares, R., et al

The skin is the largest organ in the body and consists of up to 20 million cell types, comprising but not limited tokeratinocytes, Langerhans cells, dendritic cells, T cells, and mast cells. These cells hold critical functions in the skin, contributing to immunocompetence and preventing pathogens from entering.

However, this also would prevent antigen delivery in the circumstance of vaccine development. Overcoming the stratum corneum barrier for transdermal permeability has been a focal point for researchers who have developed innovative technologies, such as iontophoresis, sonophoresis, and magnetophoresis electroporation, and laser microporation.

These methods can be effective but have their own limitations. For example, they are economically inefficient, and due to this, the most ubiquitous method for the administration of micro- and macromolecules via the skin has been the use of microneedles.

While microneedles can be effective, it is not considered to be completely needle-free and so with the emergence of the innovative field of nanotechnology, optimized nanosystems have been developed to cross the skin barrier without the dependence on invasive techniques.

Nanosystems which have been used for antigen delivery have been researched within literature and include nanoparticles and liposomes. Liposomes can be utilized effectively to transport antigens within parenteral administration;however, their use for needle-free transdermal immunization can be less effective.

This is due to their rigid structure which makes them inefficient for crossing the skin barrier, though incorporating nanotechnology within this nano-sized delivery particle, can allow this obstacle to be overcome.

Transferosomes are elastic liposomes that consist of phospholipidsthat form deformable vesicles. This mode of antigen delivery can be promising for use within the transdermal route as these particles can increase transdermal permeability in the stratum corneum in the presence of a hydration gradient.

Intriguingly, the biological makeup of transferosomes includes being highly flexible, effective for encapsulating hydrophobic and hydrophilic compounds as well peptides, and most importantly, they can pass through the pores of the skin. These key characteristics make transferosomes a perfect candidate for needle-free antigen delivery.

While there are significant benefits utilizing nanosized particles for nanovaccine development in innovative alternatives for parenteral antigen delivery within vaccinations, this area still requires further research.

Nanomedicine has innovated several fields of medicine, and this has benefitted research into the quality of patient care; however, the current state of medicine has proven immunizations of entire populations to be the most cost-effective method in disease prevention. This route can only be challenged with a collaborative effort with production laboratories to reduce production costs.

The advancement of needle-free administration would also require further research into the size and stability of nanosystems and the optimization of strategiesto tackle designs in a short space of time with limited resources, such as through utilizing computational techniques. This would be beneficial within a pandemic where resources are being shared between countries and urgent demand for solutions.

Benefitting and improving patient care should be the highest priority of medicine and with advanced nanocarrier design and innovative researchers, transdermal vaccinations could potentially become the future of disease control.

Continue reading: Antiviral Activity of Intermetallic Nanoparticles Incorporated into Polymeric Fibers.

Valdivia-Olivares, R., Rodriguez-Fernandez, M., lvarez-Figueroa, M., Kalergis, A. and Gonzlez-Aramundiz, J., (2021)The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination.Vaccines, 9(12), p.1420. Available at: https://www.mdpi.com/2076-393X/9/12/1420

Gheibi Hayat, S. and Darroudi, M., (2019)Nanovaccine: A novel approach in immunization.Journal of Cellular Physiology, 234(8), pp.12530-12536. Available at: https://doi.org/10.1002/jcp.28120

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Here is the original post:
The Role of Nanomedicine in Transdermal Vaccine Alterantives - AZoNano

Posted in Nano Medicine | Comments Off on The Role of Nanomedicine in Transdermal Vaccine Alterantives – AZoNano